Our results show directly that increased levels of SOX9 are required to drive both tumour initiation and invasive advanced disease and that it does this in association with other oncogenic pathways such as loss of Pten. SOX9 is expressed in the normal prostate and mechanisms to achieve increased levels in tumours have been proposed. This evidence concerns the gene PTEN and neoplasm.